Shc and IRS-1 (and their relatives) are cytoplasmic docking proteins that possess phosphotyrosine-binding (PTB) domains, through which they bind speci®c activated receptor tyrosine kinases (RTK). The subsequent phosphorylation of Shc or IRS-1 creates binding sites for the SH2 domains of multiple signaling proteins, leading to the activation of intracellular biochemical pathways. The PTB domains of Shc and IRS-1 both recognize autophosphorylation sites in RTKs with the consensus sequence NPXpY, but show distinct abilities to bind stably to RTKs such as the TrkA nerve growth factor receptor and the insulin receptor. In vitro analysis has suggested that residues N-terminal to the NPXpY motif may determine the anity with which phosphopeptide ligands are recognized by the Shc and IRS-1 PTB domains. Unlike IRS-1, the Shc PTB domain binds poorly to the insulin-receptor (IR) b subunit in vitro, owing to its low anity for the NPXpY autophosphorylation site at Tyr 960 of the IR. As a consequence, Shc does not bind stably to the activated IR in cells. We show that substitution of Ser 955, ®ve residues Nterminal to the Tyr 960 autophosphorylation site (the 75 position), with Ile alters the target speci®city of the IR such that it stably associates with Shc in insulinstimulated cells. A triple substitution of the 75, 78 and 79 residues relative to Tyr 960 of the IR to the corresponding amino acids found in the Shc PTB domain binding site of TrkA results in even stronger binding of the IR to Shc in vivo. The variant IRs with enhanced ability to bind Shc showed an increased ability to activate the MAPK pathway in response to insulin stimulation. These results demonstrate that subtle dierences in residues N-terminal to NPXpY autophosphorylation sites determine the ability of RTKs to bind speci®c PTB domain proteins in vivo, and thus modify the signaling properties of activated receptors.
Introduction
The phosphotyrosine (pTyr)-binding (PTB) domain (also referred to as the PI domain) was originally identi®ed in the Shc and IRS-1 docking proteins, through its ability to recognize speci®c pTyr-containing sites on activated receptor protein tyrosine kinases (Blaikie et al., 1994; Kavanaugh and Williams, 1994; O'Neill et al., 1994; van der Geer et al., 1995) . These PTB domains are functionally similar to SH2 domains in the sense that they bind directly to short peptide motifs in a fashion that is regulated by phosphorylation of the ligand, and depends on residues¯anking the phosphorylation site (Songyang et al., 1995) . However, the structures of the Shc and IRS-1 PTB domains, and the mechanisms by which they recognize speci®c phosphopeptides, are quite dierent from those displayed by SH2 domains (Eck et al., 1996; Zhou et al., 1995) . SH2 domains possess a conserved pTyrbinding pocket, with an invariant buried Arg that coordinates the phosphate oxygens. In general, the phosphopeptide ligand lies orthogonally to a central anti-parallel b-sheet on the SH2 domain, such that peptide residues C-terminal to the pTyr contact a variable binding surface, and thereby determine the speci®city of SH2 domain-phosphopeptide interactions (Kuriyan and Cowburn, 1997) . The Shc and IRS-1 PTB domains are structurally closely related to one another, and possess a similar fold to PH domains, but are entirely distinct from SH2 domains (Eck et al., 1996; Kuriyan and Cowburn, 1997; Zhou et al., 1995) . Both of these PTB domains recognize phosphopeptides in which amino acids N-terminal to the pTyr bind as a supplementary b-strand to an antiparallel b-sheet of the PTB module; the NPXpY motif then forms a bturn, positioning the phosphorylated Tyr for interaction with solvent exposed basic residues. In the Shc and IRS-1 PTB domains dierent residues recognize the bound pTyr, suggesting that these individual PTB domains might have independently acquired an ability to recognize phosphorylated Tyr (Eck et al., 1996; Zhou et al., 1995) . Consistent with this view, PTB domains from proteins such as X11, Fe65 and Numb can bind tightly to non-phosphorylated peptides (Borg et al., 1996; Fiore et al., 1995; Li et al., 1997) , suggesting that PTB domains may have originally developed as modules that recognize peptides with bturn structures, independently of phosphorylation. The diversity of peptide ligands recognized by PTB domains, and the signi®cant biological functions attributed to PTB-containing proteins, makes it important to understand the speci®city of ligand recognition in vivo.
Despite their common ability to recognize NPXpY motifs, Shc and IRS-1 show distinct speci®cities in their binding to phosphopeptides in vitro (He et al., 1995; van der Geer et al., 1996a; Wolf et al., 1995) . The Shc PTB domain requires a large aliphatic amino acid at the 75 position (®ve residues N-terminal to the pTyr), which occupies a hydrophobic pocket on the PTB domain (van der Geer et al., 1996a; Zhou et al., 1995) , whereas the IRS-1 PTB domain binds preferentially to phosphopeptide ligands with hydrophobic residues at the 76 to 78 positions (He et al., 1995) . Presumably as a consequence of this distinction in binding properties, Shc and IRS-1 show dierent interactions with receptor protein-tyrosine kinases. Thus Shc binds stably to TrkA, the nerve growth factor receptor, which has a juxtamembrane autophosphorylation site (Tyr 490) with the sequence QGHIIENPQY (Stephens et al., 1994) . This interaction results in Shc tyrosine phosphorylation at sites that engage the Grb2 SH2 domain (Stephens et al., 1994) . In contrast, IRS-1 does not interact signi®cantly with Trk receptors, but rather binds through its PTB domain to a juxtamembrane autophosphorylation site (Tyr 960) on the b subunit of the insulin receptor (IR) in the sequence PLYASSNPEY (Feener et al., 1993; O'Neill et al., 1994; White et al., 1988) . At physiological levels of IR, this PTB-mediated interaction is required for phosphorylation of IRS-1 at multiple sites, that subsequently bind a range of SH2-containing proteins, most notably phosphatidylinositol 3'-kinase (Backer et al., 1992) . Although Shc becomes phosphorylated in cultured cells stimulated with insulin, Shc does not bind stably to the activated IR and is reportedly not signi®cantly responsive to insulin stimulation in the rat (Di Guglielmo et al., 1994) . Our previous work with phosphopeptides modeled on the TrkA and IR PTB-binding sites has suggested that the presence of a Ser residue at the 75 position of the IR Tyr 960 autophosphorylation site blocks binding to the Shc PTB domain (van der Geer et al., 1996a). Substitution of this residue with Ile, as found at the corresponding position of the PTB binding site on TrkA, confers high anity binding of peptides to the Shc PTB domain in vitro (van der Geer et al., 1996a).
Results and discussion
To investigate the residues that act as speci®city determinants for Shc PTB-binding in cells, and to pursue the relevance of the Shc pathway to signaling in vivo, we have tested the consequences of substituting Ser 955 of the IR b-subunit, the 75 residue relative to Tyr 960, with Ile. We made a second mutant, containing the S955I substitution, in which Pro951 and Leu952 (at the 79 and 78 positions) were also changed to Gln and Gly respectively. This latter mutant incorporates additional residues found in the TrkA Tyr490 autophosphorylation site. Expression vectors encoding wild type IR or mutants with either the S955I substitution or with the combined P951Q/ L952G/S955I changes, were transiently transfected into COS1 cells. Wild type and mutant receptors were expressed at very similar levels ( Figure 1 ). Stimulation with insulin elicited similar levels of tyrosine phosphorylation of the IR b-subunit, re¯ecting normal receptor autophosphorylation, regardless of the presence of substitutions at residues 951 ± 955.
To investigate the role of the 75, 78 and 79 residues in the PTB mediated binding of Shc to the activated IR, Wt and mutant IRs were expressed together with HA-tagged Shc by transient transfection in COS1 cells. HA-tagged Shc was immunoprecipitated from control and insulin-stimulated cells. Associated proteins were visualized by immunoblotting with antibodies to pTyr and to the b subunit of the IR. As judged by this assay, Shc was not detectably associated with the wild type receptor. In contrast, Shc was readily detected in a stable complex with the S955I variant of the IR, and yet higher levels of the triply mutated IR b-subunit were precipitated with Shc ( Figure 2 ) In both cases Shc-binding was largely dependent on insulin stimulation, although a weak interaction was observed even prior to insulin addition, possibly due to basal receptor autophosphorylation. These results strongly argue that the residue at 955 of the IR (at the 75 position of the PTB-binding site), and to a lesser extent the residues at 951 and 952, play a critical role in determining PTB-binding speci®city of the IR in vivo. In the wild type receptor, a Ser at 75 blocks high anity Shc PTB binding, but is permissive for the IRS-1 PTB domain. However, changing this Ser to Ile results in a variant IR that binds stably to Shc in cells, following receptor autophosphorylation. Thus the speci®city of the IR for its cytoplasmic PTB domain targets can be re-engineered in vivo by altering a single residue in the PTB-binding site.
The acquisition of a high anity binding site for the Shc PTB domain might be expected to confer altered signaling properties on the insulin receptor. Shc has two potential binding sites for the Grb2 SH2 domain, at Tyr 317 and Tyr 239/240, of which the Tyr 239/240 site has a particularly high anity for Grb2. Tyrosine phosphorylation of Shc results in prominent recruitment of the Grb2/Sos1 complex, and has therefore been implicated in activation of the Ras/MAPK pathway. In contrast, IRS-1 has a single Grb2-binding site. Insulin stimulation of COS1 cells expressing the wild type IR induced tyrosine phosphorylation of MAPK, a marker for activation of the Ras pathway. The tyrosine phosphorylation of MAPK in response to insulin was enhanced in cells expressing the S955I or P951Q/ L952G/S951 mutants (Figure 3) , suggesting that the Ras/MAPK pathway was more potently stimulated in Figure 2 Substitution of the polar Ser residue at the 75 position relative to Tyr 960 with Ile induces stable binding of the activated insulin-receptor to Shc. Wild type or mutant insulin receptors were co-expressed with HA-tagged Shc by transient transfection in COS1 cells (wild type receptors, lanes 1 and 2; S955I, lanes 3 and 4; P951Q/L952G/S955I, lanes 5 and 6, vector control lanes 7 and 8). HA-tagged Shc was isolated by immunoprecipitation from serum starved control cells (lanes 1, 3, 5 and 7) and insulin stimulated cells (lanes 2, 4, 6 and 8). Immunoprecipitates were probed with an antibody against pTyr (a), an antiserum against the insulin receptor (b) and an antiserum against Shc (c) cells expressing mutant receptors that bind stably to the Shc PTB domain. Although the extent of MAPK activation was signi®cantly enhanced in cells expressing the mutant receptors, there was no marked alteration in the concentration of insulin required to elicit detectable MAPK phosphorylation (data not shown). As a more quantitative measure of MAPK activation, we assessed the in vitro kinase activity of MAPK using a peptide, derived from myelin basic protein, as a substrate for phosphorylation. For this purpose, HA-tagged MAPK was co-transfected with wild type or mutant IR and Shc into COS1 cells; the cells were then stimulated with insulin, and MAPK was immunoprecipitated with an anti-HA antibody and subjected to an in vitro kinase assay. In this assay, the mutant receptors were approximately 1.5 ± 2.0 times more active than wild type receptor in inducing MAPK activation (Figure 4 ). These data suggest that the provision of the IR with a high anity binding site for the Shc PTB domain enhances its ability to activate the MAPK pathway.
PTB domains, like SH2 domains, bind pTyr in a sequence speci®c context. Previous work has suggested that the speci®city of receptor-SH2 interactions is controlled by residues C-terminal to autophosphorylation sites in the receptor, and by speci®c amino acids in the SH2 domain which dictate the shape of its ligandbinding surface. The physiological activities of receptors and SH2 domain signaling proteins depend on the nature of these interactions. A number of receptor tyrosine kinases bind proteins with PTB domains through NPXpY autophosphorylation sites, and as a consequence increase the availability of SH2 domain binding sites through subsequent phosphorylation of the PTB-containing protein (Pawson and Scott, 1997) . The use of speci®c phosphopeptides and degenerate peptide libraries, and solution of the structures of PTB domains in association with ligands, has suggested that subtle dierences in the sequence N-terminal to the NPXpY motif can have signi®cant eects on the anity and speci®city of PTB binding (Eck et al., 1996; He et al., 1995; Wolf et al., 1995; Zhou et al., 1995) . We have pursued the relevance of these in vitro ®ndings to the binding properties and biological activity of the IR in cells. The data indicate that the IR is designed to bind IRS-1 at the expense of Shc, and show that the IR can be readily converted to a form able to stably complex with Shc in insulin-stimulated cells. This re-design of IR targeting properties can be achieved through a single amino acid substitution that reverses the speci®city of the IR for Shc, as compared to IRS-1 PTB domains. Functional analysis of cells expressing wild type or mutant receptors indicates that the preference displayed by the wild type IR for IRS-1, and its discrimination against Shc, may be biologically important, as the S955I IR is more potent in activating the MAPK pathway. It will be of interest to determine whether a similar situation pertains for the insulin-like growth factor 1 receptor, which has a juxtamembrane PTB domain-binding motif that is similar to that of the insulin receptor.
These results are consistent with the notion that closely related modular domains are used repeatedly in signaling pathways from cell surface receptors. Biochemical and biological speci®city in signal transduction can apparently be conferred by subtle changes in the docking sites on activated receptors which modify their binding anity for modular pTyr recognition domains.
Materials and methods

Cells lines and antibodies
COS1 cells were grown in DMEM 10% CS. A polyclonal anti-Shc serum was raised against a GST-Shc SH2 fusion protein (Pelicci et al., 1992) . A monoclonal antibody (29B4) and a polyclonal serum (anti-C19) that recognize the human insulin receptor were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Monoclonal antibodies 4G10, against pTyr, and B9, against p42 MAPK were purchased from UBI (Lake Placid, NY, USA). Monoclonal antibody 12CA5 against the HA epitope was purchased from Babco (Richmond, CA, USA).
Expression of wild type and mutant insulin receptors, HAtagged Shc and HA-tagged MAPK in mammalian cells
The insulin receptor cDNA was obtained from C Yip (University of Toronto), point mutants were introduced by PCR, mutant fragments were sequenced to ensure ®delity and cloned back into the full length cDNA. Insulin receptor cDNAs were then cloned into pcDNA3. COS1 cells at 50% con¯uence were transfected with 5 mg pcDNA3 containing the insulin receptor with or without 5 mg pcDNA3 HA-Shc or 5 mg pMT HA MAPK; transfections were carried out using Lipofectin and Optimem (Gibco ± BRL, Gaithersburg, MD, USA) according to manufacturers directions. Cells were lysed 72 h after transfection.
Immunoprecipitation and immunoblotting
Cells were starved 48 h after transfection in DMEM 20 mM HEPES pH 7.2. Control cells or cells stimulated with 100 nM insulin for 5 min at 378C were lysed in PLC-lysis buer and immunoprecipitations were carried out, resolved by SDS ± PAGE and transferred to PVDF membranes exactly as described before (van der Geer et al., 1996b) . Membranes were blocked for 1 h at room temperature in 10 mM Tris/Cl pH 7.4, 150 mM NaCl, 0.2% Tween 20 (TBST) containing 5% dried milk and incubated with 1 : 200 to 1 : 500 dilution of antisera in TBST 5% milk for 1 h at room temperature. Blots were washed 2610 min with TBST and 265 min with 10 mM Tris/Cl pH 7.4 and 150 mM NaCl (TBS). Membranes were then incubated for 1 h with HRP-Protein A or HRPGoat anti-mouse Ig (Biorad, Hercules, CA, USA) diluted 1 : 10 000 in TBST and washed as before. Reactive proteins were visualized by ECL (Amersham Arlington Heights, IL, USA). For immunoblotting with anti-pTyr serum, membranes were blocked with TBST containing 5% Bovine serum albumin (BSA) followed by an incubation with the antiserum diluted in TBST 5% BSA. Washes and detection were done exactly as described for other antisera.
Analysis of MAPK activity in COS1 cells
COS1 cells were transfected with pMT HA-MAPK in addition to other constructs. Cells were starved for 24 h and control and insulin-stimulated cells were lysed in HO lysis buer (50 mM HEPES, pH 7.5, 100 mM NaCl, 1% NP40, 2 mM EDTA, 100 mM Na 3 VO 4 , 1 mg/ml leupeptin, 1 mg/ml Aprotinin and 1 mM PMSF). MAPK was immunoprecipitated by incubation with monoclonal 12CA5 against the HA epitope. Immunoprecipitates were washed twice with HO lysis buer and twice with 10 mM HEPES pH 7.5 containing 10 mM MgAcetate and subsequently incubated for 15 min at 378C with 30 ml kinase mix (20 mM HEPES pH 7.4, 10 mM MgAcetate, 1 mM DTT, 25 mM ATP, 0.5 mg/ ml MBP and 1 ml [g 32 P]ATP per reaction), 5 ml aliquots were spotted onto phosphocellulose paper, washed several times in 75 mM phosphoric acid and the radioactivity incorporated in MBP was quanti®ed by Cerenkov counting.
